BioCentury | Jul 31, 2020
Distillery Therapeutics

ADORA2B agonism for obesity and aging-induced sarcopenia

...DISEASE CATEGORY: Endocrine/metabolic; musculoskeletal INDICATION: Obesity; musculoskeletal Promoting adenosine signaling through ADORA2B could treat obesity and...
...treat obesity and aging-induced sarcopenia. In brown adipose tissue biopsies from lean and overweight individuals, ADORA2B...
...markers in aged mice. Ongoing work includes medicinal chemistry to develop novel ADORA2B agonists. TARGET/MARKER/PATHWAY: Adenosine A2B receptor (ADORA2B)...
BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

Among four new biotech listings Friday, three priced upsized IPOs that each delivered more than $200 million in proceeds, but none of the quartet enjoyed the kind of satisfying first-day pop other biotechs have had...
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

June has already seen 13 biopharmas raise more than a total of $4.7 billion from NASDAQ IPOs, and biotechs are continuing to line up for public market debuts (see “Biotech IPOs on NASDAQ Maintain Momentum”...
BioCentury | Jun 24, 2020
Deals

Gilead gains access to tumor myeloid targets via Pionyr partnership

...pipeline includes anti-TIGIT mAb AB154; and two compounds targeting the adenosine pathway: dual ADORA2A and ADORA2B...
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

iTeos Therapeutics S.A. made several hires Tuesday, including Matthew Gall as CFO and Yvonne McGrath as VP of R&D. Gall was SVP of corporate development at Sarepta Therapeutics Inc. (NASDAQ:SRPT); McGrath was CSO of Complix...
BioCentury | May 29, 2020
Finance

Taiho’s new modality search engine

...milestones. Taiho has already exercised the option for AB928, a dual antagonist of ADORA2A and ADORA2B...
...microbiome-based therapeutics to treat cancer. Targets ADORA2A (A2AR; ADORA2) - Adenosine A2A receptor ADORA2B - Adenosine A2B receptor...
BioCentury | May 27, 2020
Top Story

Arcus keeps its independence in deal that gives Gilead access to targets ripe for combinations

...combination to treat various cancers. Its clinical programs include anti-TIGIT mAb AB154; dual ADORA2A and ADORA2B...
...Maintains Independence, Adds Firepower” ). Targets ADORA2A (A2AR; ADORA2) - Adenosine A2A receptor ADORA2B - Adenosine A2B receptor...
...Editor AB122 AB928 AB680 AB154 Gilead Sciences Inc. Arcus Biosciences Inc. T cell immunoreceptor with Ig and ITIM domains (TIGIT) Adenosine A2A receptor (ADORA2A) Adenosine A2B receptor (ADORA2B) Ecto-5'-nucleotidase...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...intervenes in this metabolic pathway. Arcus will present new Phase I/Ib data on its dual ADORA2A/ADORA2B...
...NSCLC ( No. e21659 ) Targets ADORA2A (A2AR; ADORA2) - Adenosine A2A receptor ADORA2B - Adenosine A2B receptor...
BioCentury | Apr 16, 2020
Deals

Arcus mum on report of Gilead’s approach

...inquiries on Thursday. Arcus has four clinical programs, including a dual inhibitor of ADORA2A and ADORA2B...
...March 2018 (see “Modest First-Day Pop” ). Targets ADORA2A - Adenosine A2A receptor ADORA2B - Adenosine A2B receptor...
BioCentury | Apr 14, 2020
Product Development

COVID-19 roundup: Can-Fite repurposing RA therapy; plus Brazilian chloroquine study points to cardiotoxicity, Athersys stem cell trial, Rutgers saliva test

As Can-Fite begins testing the first ADORA3 agonist against COVID-19, the latest red flag for chloroquine came with the immediate termination of the high dose arm of a Brazilian trial of the repurposed malaria drug....
Items per page:
1 - 10 of 275